24 February 2026 : Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma
I-Ji Jeong
BCEF 1, Shin Hwang ABDEF 1*, Chul-Soo Ahn BCD 1, Deok-Bog Moon BCD 1, Tae-Yong Ha ABCD 1, Gi-Won Song BCD 1, Dong-Hwan Jung BCD 1, Gil-Chun Park BCD 1, Woo-Hyoung Kang BCD 1, Young-In Yoon BCD 1, Sung-Gyu Lee BD 1
DOI: 10.12659/AOT.950997
Ann Transplant 2026; 31:e950997
Table 1 The clinicopathological profiles of patients with intrahepatic cholangiocarcinoma who underwent liver transplantation.
| Parameter | Values |
|---|---|
| Age (years) | 56.9±6.3 |
| Sex (n), Male: Female | 23: 2 |
| Background liver disease (n) | |
| HBV | 17 (68%) |
| HCV | 4 (16%) |
| ALD | 2 (8%) |
| Others | 2 (8%) |
| Pretransplant serological tumor markers | |
| Serum AFP (n=25) | |
| Mean (ng/mL) | 90.9±178.3 |
| Median (ng/mL) | 15.4 (2–678) |
| Serum PIVKA-II (n=22) | |
| Mean (mAU/mL) | 50.5±80.3 |
| Median (mAU/mL) | 22 (9–376) |
| Serum CA 19-9 (n=25) | |
| Mean (U/mL) | 42.3±46.6 |
| Median (U/mL) | 22.5 (2.6–186) |
| Serum CEA (n=21) | |
| Mean (ng/mL) | 3.1±2.4 |
| Median (ng/mL) | 2.7 (0.7–9.1) |
| MELD score | 12.5±8.3 |
| Graft type (n) | |
| Living-donor right liver graft | 19 (76%) |
| Living-donor dual liver graft | 3 (12%) |
| Whole-liver graft | 3 (12%) |
| ABO-incompatible LT (n) | 6 (24%) |
| Graft-to-recipient weight ratio | 1.04±0.21 |
| Tumor pathology | |
| ICC maximum tumor size (cm) | |
| Mean | 2.7±1.6 |
| Median | 2.2 (0.5–7.0) |
| ICC tumor number (n) | |
| One | 22 (88%) |
| Two | 2 (8%) |
| Three | 1 (4%) |
| ICC lymphovascular invasion (n) | 10 (40%) |
| ICC perineural invasion (n) | 6 (24%) |
| ICC lymph node metastasis (n) | 2 (8%) |
| ICC 8 AJCC tumor stage (n) | |
| IA | 19 (76%) |
| IB | 1 (4%) |
| II | 3 (12%) |
| IIIB | 2 (8%) |
| Very early-stage ICC (n)* | 7 (28%) |
| Type of concurrent second tumor (n) | |
| HCC | 9 (36%) |
| cHCC-CCA | 1 (4%) |
| Concurrent tumor 8 AJCC stage | |
| IA | 1 (4%) |
| IB | 5 (20%) |
| II | 4 (16%) |
| HBV – hepatitis B virus; HCV – hepatitis C virus; ALD – alcoholic liver disease; AFP – alpha-fetoprotein; PIVKA-II – proteins induced by vitamin K absence or antagonist-II; CA19-9 – carbohydrate antigen 19-9; CEA – carcinoembryonic antigen; MELD – model for end-stage liver disease; LT – liver transplantation; ICC – intrahepatic cholangiocarcinoma; AJCC – American Joint Committee on Cancer tumor staging system; HCC – hepatocellular carcinoma; cHCC-CCA – combined hepatocellular carcinoma-cholangiocarcinoma. * Concurrent second tumor was not taken into account. | |